Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
about
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsActive and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infectionPredictors of mortality in solid-organ transplant recipients with infections caused by Acinetobacter baumannii.Should we treat patients with only one set of positive blood cultures for extensively drug-resistant Acinetobacter baumannii the same as multiple sets?Draft Genome Sequence of Acinetobacter baumannii Strain ABBL099, a Multidrug-Resistant Clinical Outbreak Isolate with a Novel Multilocus Sequence Type.Genome sequences of four divergent multidrug-resistant Acinetobacter baumannii strains isolated from patients with sepsis or osteomyelitis.A bronchofiberoscopy-associated outbreak of multidrug-resistant Acinetobacter baumannii in an intensive care unit in Beijing, China.Structural Relationship of the Lipid A Acyl Groups to Activation of Murine Toll-Like Receptor 4 by Lipopolysaccharides from Pathogenic Strains of Burkholderia mallei, Acinetobacter baumannii, and Pseudomonas aeruginosa.The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection.The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infectionsWhich Multidrug-Resitant Bacteria are Emerging in Patients with Hematological Malignancies?: One-Year Report.Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance.Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremiaInhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosisUtility of Whole-Genome Sequencing in Characterizing Acinetobacter Epidemiology and Analyzing Hospital OutbreaksRisk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia.Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: Clinical characteristics and outcomeNext-Generation Epidemiology: Using Real-Time Core Genome Multilocus Sequence Typing To Support Infection Control Policy.Validation of a novel murine wound model of Acinetobacter baumannii infection.The role of antimicrobial stewardship in curbing carbapenem resistance.Whole-Genome Sequencing Elucidates Epidemiology of Nosocomial Clusters of Acinetobacter baumannii.Acinetobacter baumannii infection in solid organ transplant recipients.Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.The deadly impact of extreme drug resistance in Acinetobacter baumannii."Airborne assault": a new dimension in Acinetobacter baumannii transmission*.Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?Diabetic murine models for Acinetobacter baumannii infection.Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.Multi-locus sequence typing (MLST) of non-fermentative Gram-negative bacilli isolated from bloodstream infections in southern Poland.Extensive colonization with carbapenemase-producing microorganisms in Romanian burn patients: infectious consequences from the Colectiv fire disaster.
P2860
Q26991886-980FC614-210C-49BA-B4A6-8DDBC287C126Q27015109-28EBD9CC-00A2-49B5-906F-568DF4CF411FQ28478751-1250F8BE-8140-439B-8453-4B8AFE14C811Q33425665-CAB4041E-4DFD-426B-8BD7-93275A6EA6ECQ33443422-48DE8E5F-EF07-459F-8390-92C550BB15B3Q34168248-D977C2B2-C245-43B7-86F5-995EC4C67E71Q34178030-8B659F51-7EE3-48DC-AA19-94C14B520FCDQ34496802-C59D5ACF-6880-4B9F-BCD9-E15ACCD8A5C7Q34504085-DB3A6FF9-E641-47AC-8B42-2B24A53E18D0Q34511617-6EE0FE7D-F02E-4FE9-80F3-DB652AB9CDEFQ34634695-661AF11C-74C8-4160-8B93-9C9C61E0BE9AQ34766770-7C3E8CDA-95FF-4938-B984-5ADF5E40FBF6Q34995782-0C9D4E4A-64F3-448E-A533-CB01511A4FC8Q35270405-AF6FF830-A902-47BE-A4CB-41D42AEF599BQ35661920-02EBA47F-2916-494E-B54A-4DCD93DAB789Q36457770-242412D1-490E-4576-A896-DAADFA6CFD79Q36620884-D6480405-2361-4513-89F2-54CD11D4A66EQ36664034-A8E5E6B6-1315-49F1-B73B-93EFAA261883Q36887794-494E0ADC-FF4C-4FAC-9A62-E70A101CEBAFQ37183330-27DAB990-6E54-4FD2-8869-FB1A89D44422Q37434259-D626CB5C-1273-4364-85FB-DFC1B8138AAFQ37643643-CE1AD651-4C88-459A-BB2B-E5A7D7195476Q38125493-3420FE04-61BE-4D3F-B975-D92FF7B004B2Q40630951-7087A307-B48B-465A-9D21-31A0D0301200Q41549501-103BB9D4-0171-4AD0-8484-B2355D5FCFDFQ42245284-0A8B177B-D7C3-4A7F-979E-358CD33F3FA0Q42575612-020DFF7C-B3FA-4B4C-B333-8687397F39F2Q42924406-2229F586-8220-4EBA-9B34-F86CD794638BQ43202091-2E90FCA6-0CF5-4BCC-989C-2CCB02476BA9Q43237805-5B7FE8FE-2DCD-4933-86EA-82CDDB2AFAE7Q43563522-866AA917-4FDD-4F42-B159-E4E906665A0FQ46302328-4FA36C92-A99A-4777-B092-7AD1EFDA5F7EQ47679014-D0A411A7-69ED-4EB1-9A96-A9C48219AAFA
P2860
Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak.
@en
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak.
@nl
type
label
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak.
@en
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak.
@nl
prefLabel
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak.
@en
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak.
@nl
P2093
P2860
P356
P1476
Clinical outcomes of carbapene ...... a 2-state monoclonal outbreak
@en
P2093
John P Quinn
Mary Alice Lavin
Mirza Baig
Paul Schreckenberger
Robert A Weinstein
Sharon Welbel
Sudhir Penugonda
Sunita Mohapatra
Teresa Zembower
P2860
P304
P356
10.1086/656247
P577
2010-10-01T00:00:00Z